Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Vitamin or precursor
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 936
Molecular formula: C6H6N2O
IUPAC: pyridine-3-carboxamide
Source: PC-NIACINAMIDE
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Nicotinamide, nonpeptide vitamin B3 form/NAD precursor; distinct from nicotinic acid.
Evidence and critical reading
Reported scientific and empirical uses
Replacement and nutritional context · Skin, hair and cosmetics
Nutrition and studied skin chemoprevention in risk groups; also an aesthetic-blend ingredient.
Human evidence
ONTRAC found fewer new nonmelanoma skin cancers during treatment in high-risk people. A transplant-recipient trial did not reproduce that benefit; do not universalize.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
ONTRAC found fewer new nonmelanoma skin cancers during treatment in high-risk people. A transplant-recipient trial did not reproduce that benefit; do not universalize.
ONTRAC found fewer new nonmelanoma skin cancers during treatment in high-risk people. A transplant-recipient trial did not reproduce that benefit; do not universalize.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
500 mg · Amount per administration
- Frequency
- Twice/day
- Duration
- 12 months
- Route
- Oral
- Context
- 386 people at high skin-cancer risk; not a universal indication.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID26488693 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
500 mg · Amount per administration
- Frequency
- Twice/day
- Duration
- 12 months
- Route
- Oral
- Context
- 158 transplant recipients; negative result.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID36856616 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Do not confuse with niacin or turn oral chemoprevention evidence into an injectable regimen/longevity promise.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID26488693 · Randomized controlled trial
High skin-cancer risk.
Oral twice/day, 12 months.
23% fewer new nonmelanoma skin cancers during treatment.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 386
PMID36856616 · Randomized controlled trial
Immunosuppressed transplant recipients.
Oral twice/day, 12 months.
No keratinocyte-cancer reduction; recruitment was insufficient.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 158
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Niacinamide · 1465 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT03356483 · Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.Registry status: CompletedLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07752342 · Exploring Wellbeing Outcomes in Adolescents Using Bifidobacterium Longum, 1714™Registry status: Not yet recruitingLast update posted: October 14, 2026Query verification: October 16, 2026
NCT05398484 · Psilocybin Therapy in Advanced CancerRegistry status: RecruitingLast update posted: October 14, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-NIACINAMIDE
PubChem nicotinamide (CID 936)
October 16, 2026
- PMID26488693
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL.
October 16, 2026
- PMID36856616
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, Chadban SJ, Bowen DG, Chen AC, Damian DL.
October 16, 2026
- SEARCH-PUBMED-niacinamide
PubMed/MED targeted search: TITLE_ABS:nicotinamide AND TITLE_ABS:"skin-cancer" AND TITLE_ABS:phase
October 16, 2026